BLCO: BL1332 misses primary pain endpoint but shows relief and healing signals
Per TradingView, Bausch + Lomb's BL1332 missed its 24-hour primary pain endpoint, though both doses showed greater relief than vehicle through 72 hours.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
Bausch + Lomb (BLCO) reported that its drug BL1332 did not reach the primary pain endpoint, which was measured at 24 hours. According to TradingView, both doses produced numerically stronger relief than the vehicle across analyses running through 72 hours.
Exploratory data pointed to more complete pain relief and signs of faster corneal healing. The company will work with the FDA to decide on next steps.
why it matters
For the company this is a setback in a key program: without a confirmed primary result, the drug's path depends on regulator talks and possible further trials. Markets typically treat such outcomes cautiously, even when secondary data look encouraging.
market impact
BLCO shares: missed primary endpoint weakens the BL1332 outlook, pressuring the stock
- BLCO shares pressure down — a missed primary endpoint weakens the outlook for BL1332
tags
instruments
sources
- BLCO: BL1332 missed its primary endpoint but showed consistent pain-relief signals and exploratory healing benefits — TradingView, 19 November 2026 at 21:54 UTC
- BLCO: BL1332 missed its primary endpoint but showed consistent pain-relief and healing signals — TradingView, 19 November 2026 at 23:37 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗